{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:28:24Z","timestamp":1793820504145,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022817","name":"Lanzhou University Second Hospital","doi-asserted-by":"publisher","award":["CY2021-MS-B03"],"award-info":[{"award-number":["CY2021-MS-B03"]}],"id":[{"id":"10.13039\/100022817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105254","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:02:01Z","timestamp":1772848921000},"page":"105254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The safety and effectiveness of hypofractionated radiotherapy for localized prostate cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"221","author":[{"given":"Chunhao","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijrobp.2023.11.048","article-title":"Late toxicity of prostate ultrahypofractionated radiation therapy compared with moderate hypofractionation in a randomized trial","volume":"119","author":"Alexander","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105254_bib2","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.7150\/jca.35510","article-title":"The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial","volume":"10","author":"Alexidis","year":"2019","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.7150\/jca.37825","article-title":"Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer","volume":"11","author":"Alexidis","year":"2020","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105254_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105254_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105254_bib6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","article-title":"Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer","volume":"79","author":"Arcangeli","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105254_bib7","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105254_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s12094-022-02790-2","article-title":"Radiotherapy-related toxicity for localized prostate cancer: meta-analysis comparing conventional or moderately hypofractionated vs. ultrahypofractionated protocols","volume":"24","author":"Baccaglini","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib9","article-title":"Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: a phase I-II single institution trial","volume":"40","author":"Beaudry","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105254_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105254_bib11","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105254_bib12","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105254_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a Hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2S","key":"10.1016\/j.critrevonc.2026.105254_bib14","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1016\/j.ijrobp.2017.06.1126","article-title":"Prostate hypofractionated radiation therapy with a rectal spacer comparing moderate hypofractionation (62 Gy at 3.1 Gy per fraction) versus stereotactic irradiation (37.5 Gy at 7.5 Gy per fraction): acute toxicities from the RPAH2 randomized trial","volume":"99","author":"Chapet","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105254_bib15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103432","article-title":"Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: a systematic review and meta-analysis of the current literature","volume":"165","author":"Francolini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105254_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1097","key":"10.1016\/j.critrevonc.2026.105254_bib20","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190021","article-title":"Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity","volume":"92","author":"Franzese","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105254_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4149\/neo_2017_421","article-title":"Ultrahypofractionated CyberKnifeTM based stereotactic radiotherapy versus conventional radiotherapy in patients with prostate cancer-acute toxicity evaluation in two phase II prospective studies","volume":"64","author":"G\u0142owacki","year":"2017","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-019-1210-7","article-title":"Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation","volume":"14","author":"Ha","year":"2019","journal-title":"Radiat. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105254_bib23","first-page":"CD011462","article-title":"Hypofractionation for clinically localized prostate cancer","volume":"9","author":"Hickey","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105254_bib24","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib25","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0167-8140(23)89998-4","article-title":"Stereotactic body radiation therapy (SBRT) and hypo-fractionated radiation therapy (HFRT) outcomes for low and intermediate-risk prostate cancer (PRCA): experience at two ontario centers","volume":"186","author":"Hu","year":"2023","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105254_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105254_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.rpor.2018.06.008","article-title":"Acute toxicity and quality of life in high risk prostate cancer patients: updated results of randomized hypofractionation trial","volume":"23","author":"Karklelyte","year":"2018","journal-title":"Rep. Pract. Oncol. Radiol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105254_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105254_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ijrobp.2022.04.006","article-title":"Acute toxicity of ultrahypofractionation compared with moderate hypofractionation in prostate cancer treatment: a randomized trial","volume":"113","author":"Kwan","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.ijrobp.2008.10.087","article-title":"Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison","volume":"74","author":"Leborgne","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105254_bib32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105254_bib33","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105254_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2019.07.027","article-title":"Comparison of outcomes and toxicity between extreme and moderate radiation therapy hypofractionation in localized prostate cancer: a propensity score analysis","volume":"105","author":"Marvaso","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1756-9966-28-117","article-title":"Modeling of alpha\/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer","volume":"28","author":"Marzi","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105254_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ijrobp.2023.11.058","article-title":"Is ultrahypofractionated whole pelvis radiation therapy (WPRT) as well tolerated as conventionally fractionated WPRT in patients with prostate cancer? Early results from the HOPE trial","volume":"119","author":"Mendez","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3S","key":"10.1016\/j.critrevonc.2026.105254_bib37","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2020.07.2195","article-title":"Ultra-hypofractionated versus conventionally fractionated radiation therapy boost for patients with high-risk, localized prostate cancer: a 5-year results from randomized HYPO-PROST trial","volume":"108","author":"Milecki","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys. Suppl."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105254_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00066-023-02104-7","article-title":"Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation","volume":"200","author":"Moll","year":"2024","journal-title":"Strahl. Onkol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105254_bib39","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00432-019-02983-3","article-title":"Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients","volume":"145","author":"Nicosia","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105254_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial","volume":"64","author":"Pollack","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105254_bib41","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/curroncol29010003","article-title":"Prospective randomized phase II study of stereotactic body radiotherapy (SBRT) vs. conventional fractionated radiotherapy (CFRT) for Chinese patients with early-stage localized prostate cancer","volume":"29","author":"Poon","year":"2021","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2025.07.007","article-title":"Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study","volume":"89","author":"Ratnakumaran","year":"2026","journal-title":"Eur. Urol."},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105254_bib44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prosta siegel DA te cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.critrevonc.2026.105254_bib45","article-title":"Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"40","author":"Sinzabakira","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105254_bib46","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5603\/RPOR.a2022.0116","article-title":"Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer","volume":"27","author":"Soni","year":"2022","journal-title":"Rep. Pract. Oncol. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib47","doi-asserted-by":"crossref","unstructured":"Syndikus I., Griffin C., Philipps L., et al. Abstract 304: 10-year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016). 2023 ASCO GU. San Francisco, USA.","DOI":"10.1200\/JCO.2023.41.6_suppl.304"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105254_bib48","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105254_bib49","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib50","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002","author":"Vargas","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105254_bib51","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00066-020-01589-w","article-title":"Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities","volume":"196","author":"Vassis","year":"2020","journal-title":"Strahl. Onkol."},{"key":"10.1016\/j.critrevonc.2026.105254_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-8-94","article-title":"Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment","volume":"8","author":"Viani","year":"2013","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib53","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2021.02.011","article-title":"Clinical outcomes of the CHIRP trial: a phase II prospective randomized trial of conventionally fractionated versus moderately hypofractionated prostate and pelvic nodal radiation therapy in patients with high-risk prostate cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"issue":"10196","key":"10.1016\/j.critrevonc.2026.105254_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib55","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","article-title":"The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial","volume":"100","author":"Wilson","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105254_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2022.04.045","article-title":"Conventional versus hypofractionated radiation for high-risk prostate cancer patients (CHIRP): 24-month patient-reported outcomes of the randomized phase 2 CHIRP trial","volume":"114","author":"Yang","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105254_bib57","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.18632\/aging.202551","article-title":"Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China","volume":"13","author":"Zhong","year":"2021","journal-title":"Aging"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:46:34Z","timestamp":1775907994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":57,"alternative-id":["S1040842826001411"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105254","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and effectiveness of hypofractionated radiotherapy for localized prostate cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105254"}}